Tagged with HE

China Anticancer Bioscience is an exciting international precision oncology company, applying synthetic lethal approaches to develop targeted cancer therapies. President & CEO Dun Yang explains the company’s origins, how ACB’s approach differs from that of its competitors, and how he plans to make the firm into “China’s Genentech.”   We want…

China In May 2021 Swiss giant Roche launched the ‘Roche Accelerator’ in Shanghai, a USD 31.1 million investment aiming to foster and capitalise on China’s burgeoning life sciences start-up ecosystem.   The 5000 square metre project, Roche’s first such in-house accelerator globally, builds on the company’s sizeable existing R&D presence in…

USA Taking the example of music’s effect on Alzheimer’s disease patients, John G Singer makes the case for a more holistic approach to healthcare; focusing less on the transformative potential of individual drugs and more on value as a stream of benefits delivered through a living system.   Singer/songwriter Glen Campbell,…

Switzerland The Novartis and Roche names are synonymous with Swiss pharmaceutical innovation. But for these two Basel-based global behemoths, what value does Switzerland itself hold and what do they see as the areas in which they can truly bring value in their home market?   Roche – Driving Digital & Personalised…

Dominican Republic The rise of the Dominican Republic as a regional medtech manufacturing hub might have come as a surprise to many, but not to the insiders and executives of the Central America & Caribbean healthcare industry. With several decades of economic growth and political stability, the country has positioned itself as…

Turkey The president of the Turkish Society of Cardiology, Mustafa Kemal Erol, discusses the prevalence of cardiovascular disease, which accounts for over a third of deaths in Turkey, the improvements made after the 2008 smoking ban, and their work with the healthcare industry and academia to raise awareness and bring the…

India The latest from Indian pharma, including the year-to-year 51.5 percent growth of the pharma market in April, Lilly’s partnership with three generics makers to expand the availability of its arthritis drug baricitinib, Zydus Cadila’s upcoming approval of its COVID-19 vaccine, and the emergency use authorization for a COVID-19 antibody drug…

Singapore Kenneth Tan has been President for Asia Pacific & Japan at cancer-focused medical device player Varian since February 2019. In a recent conversation with PharmaBoardroom, Tan shared how an early passion for healthcare has blossomed into an impressive global career in pharmaceuticals and MedTech, why a multidisciplinary, collaborative and patient-centric…

Dominican Republic Alejandro Paolini, Siemens Healthineers’ managing director for Mexico, Central America and Caribbean, dives into the medical technology industry’s business model transformation, switching from selling products to services with a risk-sharing approach. In addition, he reflects on the impact of the pandemic on the company’s performance, their unique presence in Central…

Turkey Turkey’s former Minister of Health, Bülent Akarcali, outlines the country’s healthcare system evolution over the past decades, comparing the improvements to the difference between a Ford Model T to a Tesla. In addition, he explains why medical tourism is and will continue to be a big business opportunity for Turkey…

Singapore Cerecin’s Charles Stacey outlines the company’s progress in expanding its lead asset into migraine and infantile spasms, how its funding strategy has evolved, why Singapore is still a logical base, and how broader developments in the CNS landscape stand to benefit all stakeholders.   Moving to Singapore was a good…

Asia-Pacific Asia-Pacific, as home to 50 percent of the world’s new cancer cases each year and with deaths caused by cancer expected to increase by 36 percent by 2030, has a pressing need for more patient-centric, data-driven, value-based, and precise solutions in oncology. Additionally, Asian cancer patients’ healthcare needs can differ…